Table 1 Baseline characteristics of studied patients at diagnosis
Parameter | Number n = (72) | % |
|---|---|---|
Sex | ||
Male | 42 | 58.3% |
Female | 30 | 41.7% |
Clinical data | ||
Hepatomegaly | 40 | 55.6% |
Splenomegaly | 36 | 50% |
Lymphadenopathy | 56 | 77.8% |
CNS infiltration | 8 | 11.1% |
Laboratory data | Range | Mean (± SD) |
TLC (× 109/L) | 2.9–150 | 47.59(34.91) |
Hb (gm/dl) | 3.4–11.7 | 7.69(1.78) |
Platelets(× 109/L) | 12–132 | 72.42(30.35) |
Peripheral blood blasts (%) | 6–80 | 32.17(23.83) |
Blasts in B.M (%) | 36–98 | 71.39(18.57) |
Immunophenotyping (n) (%) - CD19 (72/72) (100%) - HLA-Dr (72/72) (100%) - CD10 (68/72) (94.4%) - CD34 (66/72) (91.6%) - CD20 (10/72) (13.8%) - Aberrant expression (20/72) (27.7%) • Myeloid markers (8/72) (11.1%) • T cell marker (12/72) (16.6%) | ||
Cytogenetics (n= 16/72) (22.2%) - t (9;22)(BCR/ABL) (4/72) (5.6%) - t (1;19)(TCF3/PBX1) (8/72) (11.1%) - 11q23 rearrangement (4/72) (5.6%) | ||